Document ID: chunk:federal_register_of_legislation:F2024C01228:reg:222
Version: federal_register_of_legislation:F2024C01228
Segment Type: reg
Provision Reference: reg 222
Character Range: 156115–157252

222   Vaccine                                                            Abrysvo  Injection (0.5mL)  Each 0.5mL dose contains 120 µg of stabilised prefusion F proteins (60 µg  RSV‑A and 60 µg  RSV‑B antigens)    1 dose:
      respiratory syncytial virus (RSV) stabilised prefusion F subunit                                                                                                                                                (a) at 28 to 36 weeks gestation; or
                                                                                                                                                                                                                      (b) after 36 weeks gestation, if vaccination is two weeks prior to birth.
      Circumstances
      Vaccine may be provided to a person who is pregnant

This amendment results in two occurrences of the table column headings in the table.

This compilation was editorially changed to omit the second occurrence of the table column headings from Part 2 of Schedule 1 to remove the redundant text.

[1] conjugated to tetanus toxoid carrier protein 44 μg